LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Search

PerkinElmer Inc

Suletud

SektorTervishoid

0

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad

By Trading Economics

Sissetulek

-8.6M

47M

Müük

-21M

699M

P/E

Sektori keskmine

54.418

79.874

Aktsiakasum

0.4

Dividenditootlus

0.28

Kasumimarginaal

6.675

Töötajad

11,000

EBITDA

-14M

181M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+6.15% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.28%

2.31%

Järgmine aktsia dividendi kuupäev (ex-date)

16. jaan 2026

Turustatistika

By TradingEconomics

Turukapital

976M

12B

Eelmine avamishind

0

Eelmine sulgemishind

0

Uudiste sentiment

By Acuity

16%

84%

27 / 374 Pingereas Healthcare

PerkinElmer Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. nov 2025, 15:29 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

28. nov 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28. nov 2025, 19:59 UTC

Market Talk

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

28. nov 2025, 19:47 UTC

Market Talk

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

28. nov 2025, 18:16 UTC

Market Talk

Global Equities Roundup: Market Talk

28. nov 2025, 18:16 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28. nov 2025, 18:08 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

28. nov 2025, 18:08 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28. nov 2025, 17:48 UTC

Market Talk

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

28. nov 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28. nov 2025, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

28. nov 2025, 15:51 UTC

Market Talk

Canada Household Spending Edges Lower -- Market Talk

28. nov 2025, 15:33 UTC

Market Talk

Crude Futures Gain as U.S. Market Reopens -- Market Talk

28. nov 2025, 15:21 UTC

Market Talk

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

28. nov 2025, 15:13 UTC

Market Talk

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

28. nov 2025, 15:11 UTC

Market Talk

Global Equities Roundup: Market Talk

28. nov 2025, 15:11 UTC

Market Talk

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

28. nov 2025, 14:51 UTC

Market Talk

Canada GDP Report Masks Fragile State of Economy -- Market Talk

28. nov 2025, 14:41 UTC

Market Talk

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

28. nov 2025, 14:37 UTC

Market Talk

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

28. nov 2025, 14:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. nov 2025, 14:33 UTC

Market Talk

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

28. nov 2025, 14:20 UTC

Market Talk

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

28. nov 2025, 14:10 UTC

Market Talk

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

28. nov 2025, 13:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. nov 2025, 13:39 UTC

Market Talk

Canada Trade Data Could Face Larger-Than-Normal Revisions -- Market Talk

28. nov 2025, 13:36 UTC

Market Talk

Canada's Economy Expands More Than Expected -- Market Talk

28. nov 2025, 13:29 UTC

Market Talk

CME Outage Sowing Chaos Across Markets, Trade Nations Says -- Market Talk

28. nov 2025, 13:27 UTC

Market Talk

Russia-Ukraine Peace Efforts to Have Little Impact on Oil Fundamentals -- Market Talk

28. nov 2025, 13:19 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

PerkinElmer Inc Prognoos

Hinnasiht

By TipRanks

6.15% tõus

12 kuu keskmine prognoos

Keskmine 111.1 USD  6.15%

Kõrge 125 USD

Madal 100 USD

Põhineb 11 Wall Streeti analüütiku instrumendi PerkinElmer Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

8

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

27 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat